|
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Clinical research trials and Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer. Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer clinical trial. Subjects frequently get the best healthcare possible for their Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer  Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
For Condition: Cancer
Status: Recruiting
Sponsor(s): University of Wisconsin Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining motexafin gadolinium with doxorubicin in treating patients who have recurrent or metastatic cancer.
Details: OBJECTIVES: - Determine the maximum tolerated dose of motexafin gadolinium and doxorubicin in patients with advanced malignancies. - Determine the dose-limiting toxicity of this regimen in these patients. - Determine the safety and tolerability of this regimen in these patients. - Determine the pharmacokinetics of this regimen in these patients. - Evaluate the tumor response in patients treated with this regimen. OUTLINE: This is a dose-escalation, multicenter study. Patients are assigned to 1 of 2 groups. Group A: - Course 1: Patients receive motexafin gadolinium IV over 30 minutes on days 1, 8, 9, and 10 and doxorubicin IV over 15 minutes on day 8. - Course 2: 28 days after the beginning of course 1, patients receive doxorubicin IV over 15 minutes. - Courses 3-6: Beginning 21 days after course 2, patients receive doxorubicin IV over 15 minutes on day 1 and motexafin gadolinium IV over 30 minutes on days 1-3. Treatment repeats every 21 days. Group B: - Course 1: Patients receive motexafin gadolinium IV over 30 minutes on day 1 and doxorubicin IV over 15 minutes on day 8. - Course 2: 28 days after the beginning of course 1, patients receive doxorubicin IV over 15 minutes on day 1 and motexafin gadolinium IV over 30 minutes on days 1-3. - Courses 3-6: Beginning 21 days after course 2, patients receive doxorubicin and motexafin gadolinium as in group A. Treatment in both groups continues for up to 6 courses in the absence of disease progression, unacceptable toxicity, or a cumulative doxorubicin dose of 450 mg/m^2. Cohorts of 3-6 patients receive escalating doses of doxorubicin and motexafin gadolinium until the maximum tolerated dose (MTD) is determined. The MTD is defined as the highest dose at which no more than 0 of 3 or 1 of 6 patients experience dose-limiting toxicity. Patients are followed at 1 and 2 months. PROJECTED ACCRUAL: A total of 3-48 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed advanced malignancy that is considered incurable - Recurrent or metastatic disease - Relapsed solid tumors include, but are not limited to the following sites: - Lung - Breast - Colon - Prostate - Head and neck - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 18 and over Sex - Not specified Menopausal status - Not specified Performance status: - ECOG 0-2 Life expectancy: - Not specified Hematopoietic: - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 1.5 mg/dL - AST and ALT no greater than 2 times upper limit of normal Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - LVEF greater than 45% at rest - No prior myocardial infarction - No congestive heart failure - No clinically significant ventricular arrhythmias Other: - No history of HIV infection - No history of porphyria - No glucose-6-phosphate dehydrogenase deficiency - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for at least 6 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 28 days since prior chemotherapy - No prior lifetime cumulative doxorubicin exposure of more than 300 mg/m^2 - No other concurrent cytotoxic chemotherapy Endocrine therapy: - Not specified Radiotherapy: - At least 28 days since prior radiotherapy - No concurrent radiotherapy Surgery: - No concurrent surgery Other: - At least 14 days since prior multidrug resistance-modulating drugs (e.g., PSC833 or cyclosporine) - No other concurrent antineoplastic or investigational agents
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MarkusRenschler, Study Chair, Pharmacyclics
University of Wisconsin Comprehensive Cancer Center *Recruiting*
Madison, Wisconsin, 53792
United States
Recruiting James Thomas 608-265-8756
Hillman Cancer Center at University of Pittsburgh Cancer Institute *Recruiting*
Pittsburgh, Pennsylvania, 15232
United States
Recruiting Ramesh Ramanathan 412-648-6507
Additional Information:
Study ID Numbers: CDR0000069322; WCCC-CO-01910,PCI-PCYC-0207,NCI-G02-2061
Study Start Date:
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00036790
Other Cancer Studies:
1. REST: Reducing End-of-Life Symptoms with Touch
2. Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
3. Promoting Healthy Lifestyles
4. Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
5. Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
Related Studies:
Other Cancer Clinical Trials
Other Pennsylvania Clinical Trials
Other Pittsburgh Clinical Trials
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
|
|
|
|
|
|
|
|
